1. Introduction
The excessive apical trabeculation of the left ventricle (LVET) is known to have a broad spectrum of clinical manifestations; individuals with this morphology may experience heart failure with reduced LV ejection fraction (EF) and arrhythmic or thromboembolic events [
1,
2]. On the other end of this spectrum, a considerable part of the population lives with LVET morphology and preserved LVEF without experiencing any symptoms throughout their life [
2,
3]. However, differentiating between a healthy individual with an increased amount of trabeculae and asymptomatic, primary LVET individuals that are likely to develop complications can be challenging. As detailed in the current cardiomyopathy guideline published by the European Society of Cardiology, proper risk assessment is essential in order to avoid over-diagnosing and determine whether a LVET patient needs regular follow-ups or medical treatment [
4].
As part of the algorithm, cardiac magnetic resonance imaging (CMR) plays a substantial role not only in the diagnosis of the condition but in the risk stratification process as well since changes in the volumetric and functional parameters are considered to be alarming red flags. Genetic testing, becoming more and more accessible, is also aiding clinicians in this decision-making process, although it is worth mentioning that individuals with pathogenic LVET mutations may also be asymptomatic with preserved LVEF [
2,
5,
6,
7].
Finally, an important part of this risk assessment is the analysis of electrocardiogram (ECG) and Holter examinations, as well as the investigation of the personal and family medical history of arrhythmic events [
5,
6]. Compared to the noncompact cardiomyopathy (NCMP) population with reduced LVEF, where branch blocks, malignant ventricular arrhythmias and sudden cardiac death (SCD) are known to be of higher prevalence, the literature data on the ECG characteristics of LVET individuals with preserved LVEF is very limited [
8,
9,
10,
11]. Furthermore, the intersex difference of ECG parameters is an underexplored area, as well.
Thus, our aim was to compare the ECG characteristics and CMR parameters of LVET individuals with preserved LVEF to a control (C) group, to identify sex-specific differences, and to compare the genetic subgroups of LVET with each other and with a C population.
2. Materials and Methods
2.1. Study Population
Our team maintains a detailed database of individuals with LVET morphology confirmed by CMR. In our retrospective study, we enrolled 69 (29 female, mean age: 37.7 ± 13.9 years) LVET individuals from this database (
Table 1). Inclusion criteria were fulfilling both the Petersen and the Jacquier criteria for noncompaction normal LV and RV end-diastolic volumes and preserved ejection fraction (LVEF > 50%) [
12,
13,
14]. We have excluded patients with reduced LVEF (LVEF < 50%); congenital, ischemic or significant valvular heart diseases; hypertension; other cardiomyopathies; sports activity exceeding 6 h/week; relevant extracardiac comorbidities, as well as conditions that can cause secondary hypetrabeculation, or patients whose CMR images were not usable due to technical reasons (i.e., artefacts, contrast administration before the short axis sequence) [
15]. We also excluded subjects who were under medications known to elongate the QT. Based on the genetic testing results, the LVET group was divided into three subgroups detailed in the
Section 2.4.
Regarding the control (C) group (69 individuals, 29 female, mean age: 38.2 ± 13.5 years), we carefully reviewed the anamnestic data of the population and included only individuals without comorbidities (e.g., hypertension, ischemic heart disease, cardiomyopathy, congenital anomalies, extracardiac disorders, etc.) with no abnormalities on the cardiac MRI and <6 h/week of sports activity (
Table 1).
All procedures performed in this study were in accordance with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Ethical approval was obtained from the Medical Research Council of Hungary and issued by the National Institute of Pharmacy and Nutrition. All participants (or their legal guardians) provided informed written consent. The patient data, including the ECG recordings, CMR examinations, genetic results and medical records, were accessed during the data collection from 2 October 2023 to 31 January 2024. All data that could identify individuals in the study were only accessed by the lead investigator (A.S.).
2.2. ECG Registration and Analysis
All subjects had 12-lead ECGs taken with a 25 mm/sec paper speed using Heart Screen 112 C-1 (Innomed Medical, Budapest, Hungary) and BTL 08-LC (BTL Industries, Stevenage, UK) ECG machines. All measurements were made manually using an ECG ruler by two independent readers, K.G. and K.A.F-S. To evaluate interobserver variability, 35 ECG registrations were assessed by both examiners, demonstrating excellent agreement across all parameters (
Table S1). We calculated the average of five representative beats for each parameter, avoiding extrasystolic beats. Of the studied parameters, we measured the heart rate, the duration of the P and T waves, the PQ and QT interval and the amplitude of the P and T wave in lead II. QRS was measured in the lead, where it appeared the widest; in most cases, it was in either V3 or V4. The corrected QT (QTc) was calculated via the Bazett method. The left and right ventricular (RV) Sokolow–Lyon index (SI) was calculated by using leads V1 and V6. The ECGs were also analyzed for any signs suggestive of arrhythmia or intraventricular conduction disorder. We used the recommendations published by the American Hearts Association, American College of Cardiology Foundation and Heart Rhythm Society for reference values [
16,
17,
18].
2.3. CMR Image Acquisition and Analysis
The CMR images were acquired using Magnetom Aera (Siemens Healthineers, Erlangen, Germany) and Achieva (Philips Medical System, Eindhoven, The Netherlands) 1,5T MR imaging machines. Conventional four-, three- and two-chamber long-axis cine loops, as well as short-axis (SA) cine images covering the whole LV and RV were recorded in breath-pause using retrospectively gated balanced steady-state free precession sequences. The slice thickness was 8 mm without an interslice gap, and the field of view was 350 mm on average, adapted to the body size. After the SA cine images were acquired, either gadobutrol (Gadovist, Bayer-Schering, 0.16 mL/kg) or gadobenate dimenglumine (MultiHance, Bracco, 0.25 mL/kg) was injected intravenously. Contrast agent was administered only to patients in the LVET group and only when it held added diagnostic value. The administration was performed after the short-axis cine loops to achieve the best analytic accuracy during post-processing. Late gadolinium enhancement was evaluated in each LVET subject. Overall, LGE was detected in 5 individuals showing a subepicardial or mid-myocardial pattern; however, due to the low number of cases, we performed no further investigation in this area.
The image analysis was performed using the Medis Suite software (Medis Suite QMass, version 4.0, Medis Medical Imaging Systems, Leiden, The Netherlands).
During post-processing, the endocardial and epicardial tracings were made on the SA images in both the end-diastolic and end-systolic frames. We used a semi-automatic contouring technique with manual correction to fit the endo- and epicardial tracings to the inner and outer borders of the compact myocardium, respectively. The adjustments were made by two experienced readers: A.S., 14 years of experience, and Ba.M., with 4 years of experience. To evaluate interobserver variability, 20 CMR examinations were assessed by both examiners, demonstrating excellent agreement across all parameters (
Table S1). The MassK algorithm was used, which is a threshold-based technique that analyzes each voxel and classifies them as either myocardial tissue or blood tissue (
Figure 1). Therefore, the total myocardial mass (TM) represents the myocardial tissue within the epicardial border; while the trabeculated and papillary muscle mass (TPM) represents the myocardial tissue within the endocardial border. Both parameters were calculated by using the end-diastolic frame. Besides the muscle mass values, the software calculates the LV and RV end-diastolic, end-systolic and stroke volumes (EDV, ESV, SV) and the ejection fraction (EF). All volumetric and myocardial mass parameters were indexed to the body surface area (i). For reference values, we used the normal ranges established by Alfakih [
19].
2.4. Genetic Testing
Genetic testing was performed on 55 symptomatic LVET subjects by using peripheral blood samples. For the analyses, we applied the next-generation sequencing method by using the TrueSight Cardio Sequencing kit (Illumina, CA, USA), which contained 174 genes previously associated with cardiovascular diseases.
During the sequencing reaction, paired-end reads of 150 nucleotides in length were synthesized. The fastq files converted from optical information were quality-controlled by using FastQC (v0.11.9) and MultiQC (v1.9) software. The obtained genetic information was compared to the GRCh37.p13 assembly version of reference genome hg19 with BWA software (v0.7.12). The Broad Institute GATK software (v4.1.7.0) was used to detect mutations, which was followed by manual variant screening.
The ClinGen and OMIM databases were used to identify the genes associated with CMP, and the genetic variants were assessed by using Franklin, ClinVar and VarSome databases following the recommendations of the American College of Medical Genetics and Genomics (ACMG) [
20]. All variants were classified as either pathogenic (P), likely pathogenic (LP), variant of uncertain significance (VUS), likely benign and benign (B) based on clinical relevance (
Tables S2 and S3).
In accordance with the ACMG guidelines, we divided the LVET subjects into three subgroups: the P group consisted of individuals with either P or LP mutations, the VUS group consisted of subjects with VUS and the B group consisted of individuals without any of these mutations (
Table 1).
2.5. Clinical Background
In order to collect clinical and demographic data, LVET subjects filled out an anamnestic questionnaire containing both open-ended and closed questions. It included detailed questions about family and personal medical history, including arrhythmias, sudden cardiac death (SCD), implanted cardiac devices, structural or hereditary cardiac diseases, myocardial infarction, thromboembolic events, syncope, dizziness, chest pain and palpitation. The questionnaire also covered comorbidities, such as diabetes mellitus, kidney, hepatic, gastrointestinal, pulmonary, neurologic, endocrine, oncologic, rheumatic, autoimmune, and psychiatric diseases, metabolic syndromes and medications and sports activity. Furthermore, additional information was gathered by using available electronic medical records. When reviewing the medical history, we defined documented arrhythmia as conditions either diagnosed by Holter or ECG or those requiring treatment.
2.6. Statistical Analysis
All continuous parameters are reported as the mean ± standard deviation, and all discrete parameters are reported as counts or percentages. At first, we compared the CMR and ECG parameters between the LVET and the C groups. After that, we compared the CMR and ECG parameters of males and females in both the LVET and C groups separately. Then, we opposed the ECG parameters between the LVET and C subjects in both sexes separately. The Kolmogorov–Smirnov test was used to assess the normal distribution of continuous parameters, and Levene’s test was used to assess homogeneity. For the comparison of means between the two groups, we used independent-sample t-tests and Mann–Whitney U-tests dependent on the distribution of the dataset. To assess the difference between the genetic subgroups, for normally distributed parameters, we used the one-way analysis of variance (ANOVA) with Tukey’s post hoc test or the Welch test with the Games–Howel post hoc test dependent on the equality of variances between the subgroups. In the case of the non-normally distributed parameters, we used the Kurskal–Wallis test with Dunn’s post hoc test. We used Pearson’s correlation coefficient to assess the connection between the ECG and CMR parameters. To measure the interobserver variability, we used the intraclass correlation coefficient (ICC); values above 0.75 were considered to be excellent agreement. A p-value below 0.05 was considered statistically significant. IBM SPSS Statistics (Version 28.0, Armonk, NY, USA) was used for the statistical analyses.
3. Results
In this section we will present our results firstly by phenotype then by genotype and lastly we will describe the clinical characteristics of the LVET population.
3.1. Phenotype-Based Comparisons
3.1.1. Comparison of CMR Parameters
When comparing the CMR results between the LVET population and the C group, we found all LV volumes, the RV_EDVi and RV_ESVi, as well as the LV_TMi, LV_TPMi and RV_TPMi, to be significantly increased and the LV_EF to be significantly decreased in the LVET group (
Table 2).
The intersex comparison in the LVET population showed that the males had higher volumes and mass values in both LV and RV. In the C population, we only found significant intersex differences in the TPMi and TMi parameters (
Table 2).
When examining the relationship between the volumetric and mass values of the LVET population, we found a good correlation between these CMR parameters (
Table S4).
3.1.2. Comparison of ECG Parameters
Regarding the comparison of ECG parameters between the LVET and C groups, the duration of the P wave, the QRS, the QT and the QTc were significantly longer, the P and T wave amplitudes were significantly lower and the RV_SI was significantly higher (
Table 2).
When examining the relationship between ECG and CMR parameters, we found that the QRS duration and the LV_SI and RV_SI showed a significant but overall moderate correlation with the volumetric and the muscle mass CMR parameters (
Table 3).
Regarding the male population, in subjects with the LVET morphology, the P wave, the QRS, the QT and the QTc durations were significantly longer, the P and T wave amplitudes were significantly lower and the RV_SI was significantly higher compared to C. However, in the female population, only the QTc duration and the T wave amplitude showed significant differences between the LVET and C groups, which were similar to those of men (
Table 2).
Then, we examined the differences between sexes regarding the ECG parameters within each population. In the LVET population, males had significantly higher P wave and QRS duration, LV_SI and RV_SI values and significantly decreased QTc duration compared to females. We found similar results in the C group, except for the QRS duration, which was comparable between the sexes (
Figure 2,
Table 2).
3.2. Genetic Aspects of the Measured Parameters
When comparing the three genetic subgroups with each other, none of the CMR parameters showed significant differences. However, among the ECG parameters, the QTc duration was significantly different between the VUS and P subgroups (
Figure 3).
We also compared the ECG parameters of each genetic subgroup with their respective control group. Regarding the B subgroup, only the P wave duration showed a significant difference compared to controls. The VUS population showed significantly higher QRS and QT durations, lower P and T wave amplitudes and a higher RV_SI than the C group. The P subgroup had a significantly longer P, QT and QTc duration, as well as lower T amplitudes (
Table 4).
Regarding the QRS duration and RV_SI, their correlation with the CMR parameters became stronger when examining the P subgroup separately (
Table S5).
3.3. ECG Characteristics and Clinical Parameters of the LVET Group
After reviewing the ECG pattern of the LVET subjects, it is notable that a third of the population had T wave inversion in at least two corresponding leads, and almost two-thirds had QRS anomalies suggestive of depolarization disorder; out of those, 40% had an incomplete right bundle branch block (RBBB). See details in
Table 5.
Regarding the clinical characteristics of the LVET group, arrhythmia had been documented in 39% of the population, and five people had experienced syncope before (vasovagal syncope episodes have been excluded) (
Table 5). One third of the LVET individuals had a positive family history, which we defined as having a blood relative who had been either diagnosed with familial cardiomyopathy, experienced SCD or had an implantable cardioverter-defibrillator (ICD) device or malignant ventricular tachycardia (
Table 5). It is worth mentioning that this ratio almost doubled if we examined the P group separately.
4. Discussion
Since LVET has a broad spectrum of clinical manifestations ranging from healthy individuals to severe heart failure, risk assessment—including the analysis of CMR, ECG examinations and genetic results—is essential to determine the optimal patient management, even in symptomless individuals. Thus, in our retrospective study, we analyzed these above-mentioned parameters in an LVET population with preserved LVEF.
4.1. Phenotype-Based Comparisons
Firstly, we compared the CMR parameters of the LVET and C groups. The LVET population had normal but elevated LV and RV volumes and higher LV and RV TPMi values but decreased LV_EF compared to the normal population, which coincides with other publications [
21,
22]. Interestingly, in contrast to our and other CMR studies, Horváth et al. found comparable RV volumes and decreased RV_EF with 3D echocardiography when compared to controls [
23,
24].
Regarding the intersex comparisons of the LVET population, the CMR results of Kiss et al. are in line with ours; namely, the LV volumetric and muscle mass parameters are elevated in males compared to females [
21]. In the C population, similarly to Gregor et al. the LV volumetric results were comparable between sexes in the same age group; however, Kiss et al. found significant differences when studying a larger cohort [
21,
25,
26]. Regarding the RV, we found no significant intersex difference in the volumes of the C group, which could be related to the lower number of subjects [
26,
27]. However, more notable is the significant difference between sexes in the volumetric and muscle mass values in the LVET population.
Secondly, we compared the ECG parameters between LVET and C groups in the whole population and also in each sex separately. Then, we examined the intersex differences in both the LVET and the C populations.
4.1.1. Horizontal and Vertical Characteristics of the Depolarization
The QRS duration was in the normal range but significantly longer in the LVET population compared to C and correlated with the LV and RV volumes and mass values; however, this trait was only characteristic of LVET men. On the contrary, the QRS duration did not differ significantly between the sexes in the C group.
The positive correlation between the QRS duration and the TPM might be explained by the fact that the more excessive the trabeculation is the longer pathway the stimulus has to pass through during systole and it is not known how far the Purkinje fibers extend into the trabeculae.
Domain et al. also compared the QRS duration of decreased LVEF NCMP patients to a healthy population and found it to be longer and correlated with the LV muscle mass, which is comparable to our results [
28]. Ergul et al. also found similar differences regarding the QRS duration of LVET children population with mixed LVEF [
29]. Hnatkova et al. examined the QRS characteristics of a healthy cohort, and contrary to our results, they found its duration to be longer in men, which may be due to the significantly larger number of subjects investigated and different measurement techniques [
30]. However, we have not found detailed literature data on the ECG characteristics of LVET subjects with preserved LVEF.
Examining the vertical parameters, while the LV-SI does not seem to be LVET-dependent, the RV_SI value was significantly higher in LVET men compared to C men; however, we found both SI values to be higher in men than women, regardless of the left ventricular phenotype. These findings are coherent with both the intersex CMR differences in TPMi and TMi values of the LVET population and the available literature data [
31]. Furthermore, similarly to the QRS duration, the SI values showed significant correlations with the LV and RV volumes and mass values of the LVET population. These findings could be corresponding to the ECG differences of the characteristic morphological features of the population, namely the normal but elevated volumes and mass parameters.
Regarding the P wave, we found it to be longer in duration but lower in amplitude in the LVET population compared to C; however, the literature data regarding the atrial characteristics of the population are limited, and the significance of this difference is yet to be studied [
29,
32].
4.1.2. Horizontal and Vertical Characteristics of the Repolarization
The QTc duration was within the normal range but significantly longer in the LVET population, and we found it to be significantly longer in females compared to males. On the one hand, the prolonged QTc is characteristic of LVET, as proven by previous studies; however, they investigated a population with mixed LVEF [
9,
29,
32]. This difference could be the reason behind our QTc durations still being in the normal range, although the significant difference compared to C may suggest subclinical changes even while the LVEF is preserved.
On the other hand, women are known to have longer QTc durations than men due to the different levels of the sexual steroid hormones, which coincide with our results in both the LVET and C groups [
33,
34].
Although the T wave duration was comparable between phenotypes, the T wave amplitude was significantly lower in LVET subjects compared to the C group regardless of their sex; however, there was no intersex difference in either population. Ezaki et al. studied the intersex differences of the T wave amplitude in adolescence in a large cohort and found men to have significantly higher values than women; however, they used different measurement techniques [
35].
4.2. Phenotype- and Genotype-Based Comparison
When comparing the genetic subgroups with each other, we found no significant difference in the CMR parameters, and only the QTc differed significantly out of the ECG parameters. This could be caused both by the low number of subjects in the B and P LVET subgroups compared to the VUS subgroup and the different ratios of sexes and mean age between the subgroups. Van Waning et al. and Grebur et al. had similar results when comparing the CMR parameters of LVET subjects based on genotype [
7,
36]. Miszalski-Jamka et al. found the LVEF of those carrying P mutations to be significantly lower, although it is worth mentioning that the study populations had reduced systolic LV function [
37].
However, when comparing each genetic subgroup to their age- and sex-matched C groups, we found that the depolarization and repolarization phases differed significantly in both VUS and P subgroups despite the low number of subjects. Interestingly, the B subgroup was comparable to controls in that regard. Furthermore, when examining the relationship between the QRS duration and RV_SI values and CMR parameters, the correlation was much stronger in the P group separately than in the whole LVET group. Regarding the literature data, we could not find any publications on the genotype-based comparison of the ECG parameters between the LVET and C populations.
4.3. ECG Findings and Clinical Aspects of the LVET Group
Finally, the NCMP population is known to have a higher rate of T wave anomalies, as well as a fragmented QRS morphology originating from depolarization disorders, which is associated with poor outcomes; however, they have only been studied on a population with reduced LVEF [
11,
29,
32,
38,
39]. In our study, we showed that the T wave inversion and fragmented QRS morphology, to some extent, also appear in the LVET population with preserved LVEF, although its prognostic significance in this context is yet to be studied.
Regarding the clinical characteristics, we observed a high prevalence of arrhythmic events and positive family history among the LVET population, which are considered to be alarming symptoms according to the risk-stratification protocol [
5,
6]. Grebur et al. found that the LVET individuals carrying P mutations had a higher number of these so-called “red flags”, underlining the connections between genotype and phenotype, as well as the importance of genetic testing in LVET individuals with preserved LVEF [
7].
Overall, we found ECG depolarization and repolarization abnormalities characteristic to LVET, some of which seem to be sex-dependent and associated with genetic background. The literature data on the ECG characteristics of LVET with preserved LVEF are very limited, especially in the context of the above-mentioned aspects. Our findings raise the possibility of a subclinical effect of excessive trabeculation on the electrophysiology of the LVET population, especially with the relatively high prevalence of depolarization disorders, T wave inversions and arrhythmic events in the population. However, further research is needed to determine the prognostic value of these abnormalities.
4.4. Limitations
Our study’s main limitation is the relatively small number of subjects, especially when examining the different genetic subgroups separately. We are planning on expanding our LVET repository with more genetic data in the future. Secondly, the genetic testing kit available to us is only sensitive to single-nucleotide polymorphism mutations but not to copy number variations. Finally, since our study was conducted retrospectively and most of the ECGs were not stored digitally, it was impossible for us to use more modern, software-based means of measurement.
5. Conclusions
We examined the ECG and CMR parameters of an LVET group with preserved LVEF, compared them to healthy controls and investigated the sex-specific characteristics of the population and their relationship with genetics.
The LVET population had normal but elevated LV and RV volumes and higher TPMi values but decreased LV_EF compared to the normal population, which was more pronounced in males compared to females. The QRS duration and the RV_SI were significantly increased in LVET males compared to both females and C, and they correlated with the LV and RV volumes and muscle mass values. The QTc duration was significantly longer in the LVET population, and—similarly to the healthy population—we found it to be significantly longer in females compared to males. The T wave amplitude was significantly lower in LVET subjects compared to the C group without an intersex difference.
Of the measured CMR and ECG parameters, there were no significant differences between the genetic subgroups, and while we found the B subgroup to be comparable to C, the VUS and P subgroups differed significantly from healthy subjects in several parameters.
The subclinical changes in the ECG and CMR parameters of the LVET population, in conjunction with the high prevalence of arrhythmic events and positive family history, highlight the need for regular follow-ups even with preserved LVEF.
Supplementary Materials
The following supporting information can be downloaded at:
https://www.mdpi.com/article/10.3390/jcm13195906/s1, Table S1: Interobserver variability of the measured parameters; Table S2: Identified pathogenic and likely pathogenic mutations in cardiomyopathy-related genes in our left ventricular excessive trabeculation study population; Table S3: Identified variants of unknown significance (VUS) in cardiomyopathy-related genes in our left ventricular excessive trabeculation study population; Table S4: Correlation between the ventricular volumes and mass parameters; Table S5: The correlation of the CMR and ECG parameters in the (A) benign, (B) VUS and (C) pathogenic subgroups.
Author Contributions
Conceptualization, K.A.F.-S., K.G. and A.S.; Data curation, K.A.F.-S.; Formal analysis, K.A.F.-S., K.G., B.M. (Balázs Mester) and A.S.; Funding acquisition; H.V.; Investigation, K.A.F.-S., K.G., F.K.G. and A.S.; Methodology, K.A.F.-S., K.G. and A.S.; Project administration, K.A.F.-S. and A.S.; Resources C.B., H.V. and B.M. (Béla Merkely); Supervision, A.S.; Validation, A.S.; Visualization, K.A.F.-S.; Writing—original draft, K.A.F.-S. and A.S.; Writing—review and editing, K.A.F.-S., K.G., H.V. and A.S. All authors have read and agreed to the published version of the manuscript.
Funding
The research received support from the Ministry of Innovation and Technology of Hungary through the National Research, Development and Innovation Fund (grant number TKP2021-NKTA-46).
Institutional Review Board Statement
All procedures performed in this study were in accordance with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Ethical approval was obtained from the Ethics Committee of the Medical Research Council of Hungar through the National Institute of Pharmacy and Nutrition (ID: OGYÉI/31053/2022, approval date 6 July 2022).
Informed Consent Statement
All participants were of adult age (above 18 years old) and provided informed written consent. The patient data, including the ECG recordings, CMR examinations, genetic results and medical records, were accessed during the data collection from 2 October 2023 to 31 January 2024. All data that could identify individuals in the study were only accessed by the lead investigator (A.S.).
Data Availability Statement
The original contributions presented in the study are included in the article/
Supplementary Material, further inquiries can be directed to the corresponding author.
Acknowledgments
We would like to thank the technicians who assisted during the ECG and CMR examinations and genetic testing.
Conflicts of Interest
The authors declare no conflicts of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.
References
- Ross, S.B.; Jones, K.; Blanch, B.; Puranik, R.; McGeechan, K.; Barratt, A.; Semsarian, C. A systematic review and meta-analysis of the prevalence of left ventricular non-compaction in adults. Eur. Heart J. 2020, 41, 1428–1436. [Google Scholar] [CrossRef] [PubMed]
- Petersen, S.E.; Jensen, B.; Aung, N.; Friedrich, M.G.; McMahon, C.J.; Mohiddin, S.A.; Pignatelli, R.H.; Ricci, F.; Anderson, R.H.; Bluemke, D.A. Excessive Trabeculation of the Left Ventricle: JACC: Cardiovascular Imaging Expert Panel Paper. JACC Cardiovasc. Imaging 2023, 16, 408–425. [Google Scholar] [CrossRef] [PubMed]
- Kawel, N.; Nacif, M.; Arai, A.E.; Gomes, A.S.; Hundley, W.G.; Johnson, W.C.; Prince, M.R.; Stacey, R.B.; Lima, J.A.C.; Bluemke, D.A. Trabeculated (Noncompacted) and Compact Myocardium in Adults. Circ. Cardiovasc. Imaging 2012, 5, 357–366. [Google Scholar] [CrossRef] [PubMed]
- Arbelo, E.; Protonotarios, A.; Gimeno, J.R.; Arbustini, E.; Barriales-Villa, R.; Basso, C.; Bezzina, C.R.; Biagini, E.; Blom, N.A.; de Boer, R.A.; et al. 2023 ESC Guidelines for the management of cardiomyopathies. Eur. Heart J. 2023, 44, 3503–3626. [Google Scholar] [CrossRef] [PubMed]
- Vergani, V.; Lazzeroni, D.; Peretto, G. Bridging the gap between hypertrabeculation phenotype, noncompaction phenotype and left ventricular noncompaction cardiomyopathy. J. Cardiovasc. Med. 2020, 21, 192–199. [Google Scholar] [CrossRef]
- Negri, F.; De Luca, A.; Morea, G.; Dal Ferro, M.; Faganello, G.; Vitrella, G.; Chiatto, M.; Pinamonti, B.; Aquaro, G.D.; Sinagra, G. Make a point on left ventricular noncompaction. G. Ital. Cardiol. 2018, 19, 371–378. [Google Scholar] [CrossRef]
- Grebur, K.; Mester, B.; Fekete, B.A.; Kiss, A.R.; Gregor, Z.; Horváth, M.; Farkas-Sütő, K.; Csonka, K.; Bödör, C.; Merkely, B.; et al. Genetic, clinical and imaging implications of a noncompaction phenotype population with preserved ejection fraction. Front. Cardiovasc. Med. 2024, 11, 1337378. [Google Scholar] [CrossRef]
- Stollberger, C.; Gerger, D.; Jirak, P.; Wegner, C.; Finsterer, J. Evolution of electrocardiographic abnormalities in association with neuromuscular disorders and survival in left ventricular hypertrabeculation/noncompaction. Ann. Noninvasive Electrocardiol. 2014, 19, 567–573. [Google Scholar] [CrossRef]
- Stollberger, C.; Gerger, D.; Wegner, C.; Finsterer, J. Quantitative electrocardiographic measures, neuromuscular disorders, and survival in left ventricular hypertrabeculation/noncompaction. Ann. Noninvasive Electrocardiol. 2013, 18, 251–255. [Google Scholar] [CrossRef]
- Stollberger, C.; Winkler-Dworak, M.; Blazek, G.; Finsterer, J. Association of electrocardiographic abnormalities with cardiac findings and neuromuscular disorders in left ventricular hypertrabeculation/non-compaction. Cardiology 2007, 107, 374–379. [Google Scholar] [CrossRef]
- Ning, X.H.; Tang, M.; Chen, K.P.; Hua, W.; Chen, R.H.; Sha, J.; Liu, Z.M.; Zhang, S. The prognostic significance of fragmented QRS in patients with left ventricular noncompaction cardiomyopathy. Can. J. Cardiol. 2012, 28, 508–514. [Google Scholar] [CrossRef] [PubMed]
- McDonagh, T.A.; Metra, M.; Adamo, M.; Gardner, R.S.; Baumbach, A.; Bohm, M.; Burri, H.; Butler, J.; Celutkiene, J.; Chioncel, O.; et al. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur. Heart J. 2023, 44, 3627–3639. [Google Scholar] [CrossRef] [PubMed]
- Petersen Steffen, E.; Selvanayagam Joseph, B.; Wiesmann, F.; Robson Matthew, D.; Francis Jane, M.; Anderson Robert, H.; Watkins, H.; Neubauer, S. Left Ventricular Non-Compaction. J. Am. Coll. Cardiol. 2005, 46, 101–105. [Google Scholar] [CrossRef] [PubMed]
- Jacquier, A.; Thuny, F.; Jop, B.; Giorgi, R.; Cohen, F.; Gaubert, J.Y.; Vidal, V.; Bartoli, J.M.; Habib, G.; Moulin, G. Measurement of trabeculated left ventricular mass using cardiac magnetic resonance imaging in the diagnosis of left ventricular non-compaction. Eur. Heart J. 2010, 31, 1098–1104. [Google Scholar] [CrossRef]
- Szűcs, A.; Kiss, A.R.; Suhai, F.I.; Tóth, A.; Gregor, Z.; Horváth, M.; Czimbalmos, C.; Csécs, I.; Dohy, Z.; Szabó, L.E.; et al. The effect of contrast agents on left ventricular parameters calculated by a threshold-based software module: Does it truly matter? Int. J. Cardiovasc. Imaging 2019, 35, 1683–1689. [Google Scholar] [CrossRef]
- Surawicz, B.; Childers, R.; Deal, B.J.; Gettes, L.S.; Bailey, J.J.; Gorgels, A.; Hancock, E.W.; Josephson, M.; Kligfield, P.; Kors, J.A.; et al. AHA/ACCF/HRS recommendations for the standardization and interpretation of the electrocardiogram: Part III: Intraventricular conduction disturbances: A scientific statement from the American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the American College of Cardiology Foundation; and the Heart Rhythm Society: Endorsed by the International Society for Computerized Electrocardiology. Circulation 2009, 119, e235–e240. [Google Scholar] [CrossRef]
- Rautaharju, P.M.; Surawicz, B.; Gettes, L.S.; Bailey, J.J.; Childers, R.; Deal, B.J.; Gorgels, A.; Hancock, E.W.; Josephson, M.; Kligfield, P.; et al. AHA/ACCF/HRS recommendations for the standardization and interpretation of the electrocardiogram: Part IV: The ST segment, T and U waves, and the QT interval: A scientific statement from the American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the American College of Cardiology Foundation; and the Heart Rhythm Society. Endorsed by the International Society for Computerized Electrocardiology. J. Am. Coll. Cardiol. 2009, 53, 982–991. [Google Scholar] [CrossRef]
- Hancock, E.W.; Deal, B.J.; Mirvis, D.M.; Okin, P.; Kligfield, P.; Gettes, L.S.; Bailey, J.J.; Childers, R.; Gorgels, A.; Josephson, M.; et al. AHA/ACCF/HRS recommendations for the standardization and interpretation of the electrocardiogram: Part V: Electrocardiogram changes associated with cardiac chamber hypertrophy: A scientific statement from the American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the American College of Cardiology Foundation; and the Heart Rhythm Society. Endorsed by the International Society for Computerized Electrocardiology. J. Am. Coll. Cardiol. 2009, 53, 992–1002. [Google Scholar] [CrossRef]
- Alfakih, K.; Plein, S.; Thiele, H.; Jones, T.; Ridgway, J.P.; Sivananthan, M.U. Normal human left and right ventricular dimensions for MRI as assessed by turbo gradient echo and steady-state free precession imaging sequences. J. Magn. Reason. Imaging 2003, 17, 323–329. [Google Scholar] [CrossRef]
- Richards, S.; Aziz, N.; Bale, S.; Bick, D.; Das, S.; Gastier-Foster, J.; Grody, W.W.; Hegde, M.; Lyon, E.; Spector, E.; et al. Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet. Med. 2015, 17, 405–424. [Google Scholar] [CrossRef]
- Kiss, A.R.; Gregor, Z.; Furak, A.; Toth, A.; Horvath, M.; Szabo, L.; Czimbalmos, C.; Dohy, Z.; Merkely, B.; Vago, H.; et al. Left ventricular characteristics of noncompaction phenotype patients with good ejection fraction measured with cardiac magnetic resonance. Anatol. J. Cardiol. 2021, 25, 565–571. [Google Scholar] [CrossRef] [PubMed]
- Gregor, Z.; Kiss, A.R.; Grebur, K.; Szabo, L.E.; Merkely, B.; Vago, H.; Szucs, A. MR-specific characteristics of left ventricular noncompaction and dilated cardiomyopathy. Int. J. Cardiol. 2022, 359, 69–75. [Google Scholar] [CrossRef]
- Kiss, A.R.; Gregor, Z.; Popovics, A.; Grebur, K.; Szabo, L.E.; Dohy, Z.; Kovacs, A.; Lakatos, B.K.; Merkely, B.; Vago, H.; et al. Impact of Right Ventricular Trabeculation on Right Ventricular Function in Patients with Left Ventricular Non-compaction Phenotype. Front. Cardiovasc. Med. 2022, 9, 843952. [Google Scholar] [CrossRef] [PubMed]
- Horváth, M.; Farkas-Sütő, K.; Fábián, A.; Lakatos, B.; Kiss, A.R.; Grebur, K.; Gregor, Z.; Mester, B.; Kovács, A.; Merkely, B.; et al. Highlights of right ventricular characteristics of left ventricular noncompaction using 3D echocardiography. IJC Heart Vasc. 2023, 49, 101289. [Google Scholar] [CrossRef] [PubMed]
- Gregor, Z.; Kiss, A.R.; Szabo, L.E.; Toth, A.; Grebur, K.; Horvath, M.; Dohy, Z.; Merkely, B.; Vago, H.; Szucs, A. Sex- and age- specific normal values of left ventricular functional and myocardial mass parameters using threshold-based trabeculae quantification. PLoS ONE 2021, 16, e0258362. [Google Scholar] [CrossRef] [PubMed]
- Kiss, A.R.; Gregor, Z.; Furak, A.; Szabo, L.E.; Dohy, Z.; Merkely, B.; Vago, H.; Szucs, A. Age- and Sex-Specific Characteristics of Right Ventricular Compacted and Non-compacted Myocardium by Cardiac Magnetic Resonance. Front. Cardiovasc. Med. 2021, 8, 781393. [Google Scholar] [CrossRef] [PubMed]
- Foppa, M.; Arora, G.; Gona, P.; Ashrafi, A.; Salton, C.J.; Yeon, S.B.; Blease, S.J.; Levy, D.; O’Donnell, C.J.; Manning, W.J.; et al. Right Ventricular Volumes and Systolic Function by Cardiac Magnetic Resonance and the Impact of Sex, Age, and Obesity in a Longitudinally Followed Cohort Free of Pulmonary and Cardiovascular Disease: The Framingham Heart Study. Circ. Cardiovasc. Imaging 2016, 9, e003810. [Google Scholar] [CrossRef]
- Domain, G.; Chouquet, C.; Reant, P.; Bongard, V.; Vedis, T.; Rollin, A.; Mandel, F.; Delasnerie, H.; Voglimacci-Stephanopoli, Q.; Mondoly, P.; et al. Relationships between left ventricular mass and QRS duration in diverse types of left ventricular hypertrophy. Eur. Heart J. Cardiovasc. Imaging 2022, 23, 560–568. [Google Scholar] [CrossRef]
- Ergul, Y.; Nisli, K.; Varkal, M.A.; Oner, N.; Dursun, M.; Dindar, A.; Aydogan, U.; Omeroglu, R.E. Electrocardiographic findings at initial diagnosis in children with isolated left ventricular noncompaction. Ann. Noninvasive Electrocardiol. 2011, 16, 184–191. [Google Scholar] [CrossRef]
- Hnatkova, K.; Smetana, P.; Toman, O.; Schmidt, G.; Malik, M. Sex and race differences in QRS duration. Europace 2016, 18, 1842–1849. [Google Scholar] [CrossRef]
- Jingi, A.M.; Noubiap, J.J.; Kamdem, P.; Kingue, S. Determinants and improvement of electrocardiographic diagnosis of left ventricular hypertrophy in a black African population. PLoS ONE 2014, 9, e96783. [Google Scholar] [CrossRef] [PubMed]
- Steffel, J.; Kobza, R.; Oechslin, E.; Jenni, R.; Duru, F. Electrocardiographic characteristics at initial diagnosis in patients with isolated left ventricular noncompaction. Am. J. Cardiol. 2009, 104, 984–989. [Google Scholar] [CrossRef]
- Salem, J.E.; Alexandre, J.; Bachelot, A.; Funck-Brentano, C. Influence of steroid hormones on ventricular repolarization. Pharmacol. Ther. 2016, 167, 38–47. [Google Scholar] [CrossRef] [PubMed]
- Charbit, B.; Christin-Maitre, S.; Demolis, J.L.; Soustre, E.; Young, J.; Funck-Brentano, C. Effects of testosterone on ventricular repolarization in hypogonadic men. Am. J. Cardiol. 2009, 103, 887–890. [Google Scholar] [CrossRef] [PubMed]
- Ezaki, K.; Nakagawa, M.; Taniguchi, Y.; Nagano, Y.; Teshima, Y.; Yufu, K.; Takahashi, N.; Nomura, T.; Satoh, F.; Mimata, H.; et al. Gender differences in the ST segment: Effect of androgen-deprivation therapy and possible role of testosterone. Circ. J. 2010, 74, 2448–2454. [Google Scholar] [CrossRef]
- van Waning, J.I.; Caliskan, K.; Hoedemaekers, Y.M.; van Spaendonck-Zwarts, K.Y.; Baas, A.F.; Boekholdt, S.M.; van Melle, J.P.; Teske, A.J.; Asselbergs, F.W.; Backx, A.; et al. Genetics, Clinical Features, and Long-Term Outcome of Noncompaction Cardiomyopathy. J. Am. Coll. Cardiol. 2018, 71, 711–722. [Google Scholar] [CrossRef]
- Miszalski-Jamka, K.; Jefferies, J.L.; Mazur, W.; Glowacki, J.; Hu, J.; Lazar, M.; Gibbs, R.A.; Liczko, J.; Klys, J.; Venner, E.; et al. Novel Genetic Triggers and Genotype-Phenotype Correlations in Patients with Left Ventricular Noncompaction. Circ. Cardiovasc. Genet. 2017, 10, e001763. [Google Scholar] [CrossRef]
- Ichida, F.; Hamamichi, Y.; Miyawaki, T.; Ono, Y.; Kamiya, T.; Akagi, T.; Hamada, H.; Hirose, O.; Isobe, T.; Yamada, K.; et al. Clinical features of isolated noncompaction of the ventricular myocardium: Long-term clinical course, hemodynamic properties, and genetic background. J. Am. Coll. Cardiol. 1999, 34, 233–240. [Google Scholar] [CrossRef]
- Cetin, M.S.; Ozcan Cetin, E.H.; Canpolat, U.; Cay, S.; Topaloglu, S.; Temizhan, A.; Aydogdu, S. Usefulness of Fragmented QRS Complex to Predict Arrhythmic Events and Cardiovascular Mortality in Patients with Noncompaction Cardiomyopathy. Am. J. Cardiol. 2016, 117, 1516–1523. [Google Scholar] [CrossRef]
Figure 1.
Threshold-based postprocessing method. The short-axis CMR image of an LVET individual with the threshold-based postprocessing method. The green highlight shows the LV, and the blue highlight shows the RV myocardial mass. The MassK algorithm analyzes each voxel and classifies them as either myocardial tissue or blood tissue; therefore, the highlighted myocardial tissue within the endocardial (red in the LV and yellow in the RV) border represents the TPM. Abbreviations: CMR, cardiac magnetic resonance imaging; LV, left ventricle; LVET, left ventricular excessive trabeculation; RV, right ventricle, TPM, trabeculated and papillary muscle mass.
Figure 1.
Threshold-based postprocessing method. The short-axis CMR image of an LVET individual with the threshold-based postprocessing method. The green highlight shows the LV, and the blue highlight shows the RV myocardial mass. The MassK algorithm analyzes each voxel and classifies them as either myocardial tissue or blood tissue; therefore, the highlighted myocardial tissue within the endocardial (red in the LV and yellow in the RV) border represents the TPM. Abbreviations: CMR, cardiac magnetic resonance imaging; LV, left ventricle; LVET, left ventricular excessive trabeculation; RV, right ventricle, TPM, trabeculated and papillary muscle mass.
Figure 2.
ECG characteristics in the aspect of morphology and sex. QRS_duration: LVET male characteristic; LV_SI: male characteristic, LVET independent; RV_SI: LVET male characteristic; QTc: female characteristic, prolonged in LVET; T_amplitude: characteristic to healthy controls, sex independent. Abbreviations: LVET, left ventricular excessive trabeculation; C, control population; LV, left ventricle; RV, right ventricle; SI, Sokolow–Lyon index.
Figure 2.
ECG characteristics in the aspect of morphology and sex. QRS_duration: LVET male characteristic; LV_SI: male characteristic, LVET independent; RV_SI: LVET male characteristic; QTc: female characteristic, prolonged in LVET; T_amplitude: characteristic to healthy controls, sex independent. Abbreviations: LVET, left ventricular excessive trabeculation; C, control population; LV, left ventricle; RV, right ventricle; SI, Sokolow–Lyon index.
Figure 3.
Comparisons of the (A) CMR and (B) ECG parameters between the genetic subgroups. Abbreviations: * significant at the p < 0.05 level; EDV, end-diastolic volume; EF, ejection fraction; ESV, end-systolic volume; i, indexed to body surface area; LV, left ventricle; LVET, left ventricular excessive trabeculation; QTc, corrected QT interval; RV, right ventricle; SI, Sokolow–Lyon index; SV, stroke volume; TM, total muscle mass; TPM, trabeculated and papillary muscle mass; VUS, variant of unknown significance.
Figure 3.
Comparisons of the (A) CMR and (B) ECG parameters between the genetic subgroups. Abbreviations: * significant at the p < 0.05 level; EDV, end-diastolic volume; EF, ejection fraction; ESV, end-systolic volume; i, indexed to body surface area; LV, left ventricle; LVET, left ventricular excessive trabeculation; QTc, corrected QT interval; RV, right ventricle; SI, Sokolow–Lyon index; SV, stroke volume; TM, total muscle mass; TPM, trabeculated and papillary muscle mass; VUS, variant of unknown significance.
Table 1.
Demographic data of the (A) LVET and control populations and (B) genetic subgroups.
Table 1.
Demographic data of the (A) LVET and control populations and (B) genetic subgroups.
A | LVET | Control | LVET Total vs. C Total | LVET Male vs. C Male | LVET Female vs. C Female |
---|
Total Population | Male | Female | Total Population | Male | Female | p | p | p |
---|
Number of subjects (%) | 69 (100.0) | 40 (58.0) | 29 (42.0) | 69 (100.0) | 40 (58.0) | 29 (42.0) | 1.000 | 1.000 | 1.000 |
Age (Years) | 37.7 ± 13.9 | 37.9 ± 14.5 | 37.3 ± 13.5 | 38.2 ± 13.5 | 38.8 ± 13.6 | 37.3 ± 13.4 | 0.814 | 0.776 | 0.985 |
BMI (kg/m2) | 1.9 ± 0.2 | 2.1 ± 0.2 | 1.7 ± 0.1 | 1.9 ± 0.2 | 2.0 ± 0.1 | 1.7 ± 0.1 | 0.255 | 0.228 | 0.307 |
BSA (m2) | 25.4 ± 4.4 | 26.4 ± 3.9 | 24.0 ± 4.7 | 24.4 ± 4.2 | 25.9 ± 3.8 | 22.4 ± 4.1 | 0.190 | 0.563 | 0.184 |
B | Genetic subgroups | | | | | | |
Benign | VUS | Pathogenic | p | | | | | |
Number of subjects (Female %) | 13 (30.1) | 27 (37.0) | 15 (53.3) | 0.551 | | | | | |
Age (Years) | 40.6 ± 4.1 | 39.4 ± 2.4 | 37.1 ± 4.2 | 0.789 | | | | | |
BMI (kg/m2) | 2.02 ± 0.27 | 1.98 ± 0.23 | 1.84 ± 0.20 | 0.094 | | | | | |
BSA (m2) | 26.21 ± 4.87 | 25.94 ± 4.10 | 23.37 ± 3.12 | 0.106 | | | | | |
Table 2.
CMR and ECG parameters of the studied populations.
Table 2.
CMR and ECG parameters of the studied populations.
| LVET | Control | LVET Total vs. C Total | LVET Male vs. LVET Female | C Male vs. C Female | LVET Male vs. C Male | LVET Female vs. C Female |
---|
| Total Population | Male | Female | Total Population | Male | Female | p | p | p | p | p |
---|
Number of subjects | 69 | 40 | 29 | 69 | 40 | 29 | | | | | |
LV_EDVi (ml/m2) | 76.4 ± 14.2 | 81.6 ± 13.5 | 69 ± 11.9 | 66.9 ± 10.1 | 68.6 ± 11.0 | 64.4 ± 8.4 | <0.001 * | <0.001 * | 0.094 | - | - |
LV_ESVi (ml/m2) | 27.1 ± 8.0 | 29.4 ± 7.9 | 23.7 ± 6.9 | 21.2 ± 5.4 | 21.6 ± 6.0 | 20.6 ± 4.4 | <0.001 * | 0.003 * | 0.471 | - | - |
LV_SVi (ml/m2) | 49.4 ± 8.8 | 52.2 ± 8.4 | 45.3 ± 7.8 | 45.7 ± 7.4 | 47.0 ± 8.3 | 43.8 ± 5.6 | <0.001 * | 0.001 * | 0.061 | - | - |
LV_EF (%) | 64.9 ± 5.9 | 64.2 ± 5.7 | 66.0 ± 6.3 | 68.4 ± 5.6 | 68.6 ± 6.3 | 68.1 ± 4.3 | 0.009 | 0.244 | 0.725 | - | - |
LV_TMi (g/m2) | 75.2 ± 16.8 | 85.7 ± 12.4 | 60.1 ± 8.9 | 66.7 ± 11.2 | 72.4 ± 10.1 | 58.5 ± 6.9 | <0.001 * | <0.001 * | <0.001 * | - | - |
LV_TPMi (g/m2) | 26.1 ± 7.4 | 29.4 ± 7.0 | 21.3 ± 4.9 | 20.3 ± 4.2 | 21.8 ± 4.1 | 18.0 ± 3.2 | <0.001 * | <0.001 * | <0.001 * | - | - |
RV_EDVi (ml/m2) | 71.6 ± 14.4 | 77.9 ± 13.2 | 62.5 ± 10.9 | 65.8 ± 12.6 | 67.9 ± 13.4 | 62.8 ± 11.0 | 0.014 * | <0.001 * | 0.1 | - | - |
RV_ESVi (ml/m2) | 27.0 ± 6.7 | 29.9 ± 5.9 | 22.9 ± 5.4 | 24.1 ± 6.1 | 25.2 ± 6.5 | 22.6 ± 5.3 | 0.01 * | <0.001 * | 0.089 | - | - |
RV_SVi (ml/m2) | 44.3 ± 8.9 | 47.5 ± 7.6 | 39.6 ± 8.8 | 41.6 ± 8.7 | 42.7 ± 9.5 | 40.2 ± 7.2 | 0.083 | <0.001 * | 0.238 | - | - |
RV_EF (%) | 62.0 ± 5.9 | 61.2 ± 4.6 | 63.2 ± 7.3 | 63.3 ± 5.5 | 62.8 ± 5.9 | 64.1 ± 4.9 | 0.183 | 0.207 | 0.342 | - | - |
RV_TMi (g/m2) | 36.8 ± 9.7 | 42.2 ± 8.8 | 29.4 ± 5.0 | 35.1 ± 7.1 | 38.4 ± 6.2 | 30.2 ± 5.6 | 0.479 | <0.001 * | <0.001 * | - | - |
RV_TPMi (g/m2) | 20.7 ± 7.0 | 24.8 ± 5.8 | 14.8 ± 3.4 | 18.3 ± 4.6 | 20.1 ± 4.3 | 15.7 ± 3.6 | 0.022 * | <0.001 * | <0.001 * | - | - |
P_duration (ms) | 108.3 ± 15.8 | 111.7 ± 14.8 | 103.4 ± 16.2 | 101.5 ± 13.6 | 104.8 ± 13.3 | 96.8 ± 13.0 | 0.007 * | 0.034 | 0.017 * | 0.031 * | 0.099 |
P_amplitude (mV) | 0.11 ± 0.04 | 0.11 ± 0.04 | 0.12 ± 0.04 | 0.13 ± 0.04 | 0.13 ± 0.04 | 0.13 ± 0.05 | 0.018 * | 0.085 | 0.91 | 0.005 * | 0.581 |
PQ_duration (ms) | 163.1 ± 25.6 | 166.4 ± 26.0 | 158.4 ± 24.8 | 156.8 ± 19.7 | 160.6 ± 17.9 | 151.5 ± 21.2 | 0.85 | 0.204 | 0.059 | 0.248 | 0.268 |
QRS_duration (ms) | 105.7 ± 15.8 | 112.0 ± 15.1 | 96.6 ± 12.4 | 99.5 ± 11.4 | 100.1 ± 11.4 | 98.5 ± 11.5 | 0.01 * | <0.001 * | 0.429 | <0.001 * | 0.581 |
LV_SI (mm) | 22.4 ± 8.3 | 24.9 ± 8.8 | 18.9 ± 5.8 | 23.0 ± 6.9 | 24.4 ± 6.2 | 21.0 ± 7.5 | 0.653 | 0.001 * | 0.046 * | 0.759 | 0.23 |
RV_SI (mm) | 7.2 ± 4.2 | 8.5 ± 4.1 | 5.3 ± 3.7 | 5.3 ± 2.6 | 5.9 ± 3.4 | 4.8 ± 2.1 | 0.012 * | <0.001 * | 0.049 * | 0.003 * | 0.967 |
QT (ms) | 395.5 ± 35.0 | 394.8 ± 36.3 | 396.4 ± 33.9 | 378.3 ± 26.7 | 370.3 ± 25.1 | 389.1 ± 26.3 | 0.002 * | 0.848 | 0.004 * | <0.001 * | 0.37 |
QTc (ms) | 423.3 ± 36.6 | 413.0 ± 35.1 | 438.1 ± 34.1 | 407.3 ± 24.9 | 398.7 ± 25.3 | 418.7 ± 18.7 | 0.003 * | 0.005 * | 0.002 * | 0.048 * | 0.012 * |
T_duration (ms) | 180.9 ± 29.1 | 181.9 ± 34.1 | 179.5 ± 20.6 | 176.4 ± 19.3 | 175.0 ± 18.4 | 178.3 ± 20.6 | 0.288 | 0.726 | 0.487 | 0.267 | 0.831 |
T_amplitude (mV) | 0.20 ± 0.14 | 0.20 ± 1.6 | 0.19 ± 0.12 | 0.27 ± 0.10 | 0.28 ± 0.11 | 0.26 ± 0.07 | 0.002 * | 0.832 | 0.531 | 0.025 * | 0.014 * |
Table 3.
The correlation of the CMR and ECG parameters in the LVET group.
Table 3.
The correlation of the CMR and ECG parameters in the LVET group.
LVET Group | LV_EDVi | LV_ESVi | LV_SVi | LV_EF | LV_TMi | LV_TPMi | RV_EDVi | RV_ESVi | RV_SVi | RV_EF | RV_TMi | RV_TPMi |
---|
P_duration (ms) | r | 0.037 | 0.081 | −0.014 | −0.069 | 0.097 | 0.092 | 0.189 | 0.187 | 0.099 | −0.152 | 0.215 | 0.193 |
p | 0.765 | 0.516 | 0.913 | 0.579 | 0.433 | 0.459 | 0.126 | 0.13 | 0.425 | 0.22 | 0.081 | 0.119 |
P_amplitude (mV) | r | −0.119 | −0.119 | −0.084 | 0.078 | −0.353 ** | −0.382 ** | −0.135 | −0.131 | −0.137 | −0.002 | −0.151 | −0.249 * |
p | 0.338 | 0.336 | 0.5 | 0.53 | 0.003 | 0.001 | 0.275 | 0.292 | 0.268 | 0.987 | 0.223 | 0.042 |
PQ_duration (ms) | r | −0.006 | 0.015 | −0.025 | −0.01 | 0.085 | 0.045 | 0.086 | 0.137 | 0.026 | −0.098 | 0.088 | 0.14 |
p | 0.96 | 0.902 | 0.844 | 0.936 | 0.492 | 0.715 | 0.487 | 0.268 | 0.835 | 0.429 | 0.477 | 0.258 |
QRS_duration (ms) | r | 0.269 * | 0.287 * | 0.172 | −0.214 | 0.521 ** | 0.451 ** | 0.425 ** | 0.379 ** | 0.341 ** | −0.117 | 0.446 ** | 0.427 ** |
p | 0.028 | 0.018 | 0.165 | 0.083 | <0.001 | <0.001 | <0.001 | 0.002 | 0.005 | 0.347 | <0.001 | <0.001 |
LV_SI (mm) | r | 0.349 ** | 0.241 * | 0.343 ** | −0.065 | 0.409 ** | 0.303 * | 0.198 | 0.145 | 0.271 * | 0.08 | 0.353 ** | 0.353 ** |
p | 0.004 | 0.05 | 0.004 | 0.604 | 0.001 | 0.013 | 0.108 | 0.24 | 0.026 | 0.518 | 0.003 | 0.003 |
RV_SI (mm) | r | 0.421 ** | 0.357 ** | 0.356 ** | −0.142 | 0.413 ** | 0.294 * | 0.359 ** | 0.290 * | 0.329 ** | −0.034 | 0.445 ** | 0.343 ** |
p | <0.001 | 0.003 | 0.003 | 0.252 | 0.001 | 0.016 | 0.003 | 0.017 | 0.007 | 0.787 | <0.001 | 0.004 |
QT (ms) | r | 0.196 | 0.183 | 0.15 | −0.129 | 0.196 | 0.096 | 0.232 | 0.167 | 0.251 * | 0.047 | 0.272 * | 0.161 |
p | 0.111 | 0.138 | 0.225 | 0.299 | 0.111 | 0.439 | 0.059 | 0.176 | 0.041 | 0.708 | 0.026 | 0.193 |
QTc (ms) | r | −0.114 | −0.073 | −0.117 | −0.001 | −0.227 | −0.222 | −0.111 | −0.228 | −0.021 | 0.183 | −0.128 | −0.257 * |
p | 0.358 | 0.556 | 0.347 | 0.993 | 0.064 | 0.071 | 0.371 | 0.064 | 0.864 | 0.139 | 0.301 | 0.036 |
T_duration (ms) | r | 0.113 | 0.022 | 0.161 | 0.052 | −0.009 | −0.134 | 0.144 | 0.17 | 0.127 | −0.06 | 0.137 | 0.103 |
p | 0.365 | 0.857 | 0.194 | 0.679 | 0.941 | 0.281 | 0.244 | 0.17 | 0.307 | 0.632 | 0.269 | 0.409 |
T_amplitude (mV) | r | −0.005 | −0.077 | 0.061 | 0.114 | 0.034 | −0.094 | 0.145 | 0.198 | 0.059 | −0.168 | 0.156 | 0.144 |
p | 0.966 | 0.534 | 0.623 | 0.359 | 0.786 | 0.451 | 0.243 | 0.107 | 0.638 | 0.174 | 0.208 | 0.245 |
Table 4.
ECG parameters of the genetic subgroups and their controls.
Table 4.
ECG parameters of the genetic subgroups and their controls.
| Benign Subgroup | | VUS Subgroup | | Pathogenic Subgroup | |
---|
| LVET | Control | p | LVET | Control | p | LVET | Control | p |
---|
Number of subjects | 13 | 13 | | 27 | 27 | | 15 | 15 | |
P_duration (ms) | 113.8 ± 7.7 | 99.6 ± 16.9 | <0.01 * | 108.0 ± 16.1 | 106.0 ± 11.6 | 0.611 | 109.5 ± 16.0 | 99.1 ± 10.3 | 0.043 * |
P_amplitude (mV) | 0.12 ± 0.04 | 0.12 ± 0.05 | 0.4 | 0.10 ± 0.04 | 0.13 ± 0.04 | 0.009 * | 0.12 ± 0.04 | 0.14 ± 0.04 | 0.196 |
PQ_duration (ms) | 170.7 ± 30.3 | 161.5 ± 26.6 | 0.7 | 163.2 ± 21.5 | 160.6 ± 19.5 | 0.58 | 161.6 ± 20.6 | 150.7 ± 14.0 | 0.101 |
QRS_duration (ms) | 106.2 ± 23.7 | 102.2 ± 11.4 | 0.3 | 105.7 ± 12.3 | 97.4 ± 10.4 | 0.01 * | 103.7 ± 13.1 | 95.4 ± 13.4 | 0.097 |
LV_SI (mm) | 23.0 ± 5.4 | 21.5 ± 6.8 | 0.7 | 23.1 ± 9.0 | 22.9 ± 7.1 | 0.947 | 21.7 ± 9.1 | 24.0 ± 7.6 | 0.452 |
RV_SI (mm) | 7.4 ± 4.3 | 5.0 ± 2.8 | 0.8 | 7.6 ± 4.5 | 5.3 ± 2.3 | 0.047 * | 6.0 ± 3.8 | 4.7 ± 2.5 | 0.308 |
QT (ms) | 380.7 ± 41.5 | 381.1 ± 26.0 | 0.7 | 393.4 ± 33.5 | 375.3 ± 21.8 | 0.023 * | 405.6 ± 31.0 | 374.8 ± 35.7 | 0.018 * |
QTc (ms) | 419.3 ± 45.6 | 415.3 ± 20.4 | 0.8 | 412.4 ± 35.2 | 399.9 ± 27.5 | 0.156 | 435.5 ± 24.7 | 406.3 ± 26.8 | 0.04 * |
T_duration (ms) | 173.8 ± 17.8 | 171.2 ± 21.0 | 0.4 | 177.9 ± 27.1 | 175.6 ± 22.0 | 0.738 | 190.8 ± 36.1 | 176.9 ± 15.9 | 0.184 |
T_amplitude (mV) | 0.23 ± 0.09 | 0.27 ± 0.14 | 0.6 | 0.16 ± 0.16 | 0.26 ± 0.09 | 0.014 * | 0.17 ± 0.13 | 0.27 ± 0.07 | 0.019 * |
Table 5.
Clinical parameters of the LVET group.
Table 5.
Clinical parameters of the LVET group.
| | | Number of Subjects (%) |
---|
| Total population | 69 (100) |
ECG abnormalities | P pulmonale | 1 (1.4) |
P mitrale | 7 (10.4) |
Atrioventricular block I. degree | 5 (7.2) |
Depolarization disorders | |
| fQRS | 45 (65.2) |
| LBBB | 2 (2.9) |
| RBBB | 2 (2.9) |
| Incomplete RBBB | 16 (23.2) |
| Left anterior fascicular block | 5 (7.2) |
| Preexitation | 1 (1.4) |
Repolarization abnormalities | |
| ST segment depression | 3 (4.3) |
| J point elevation | 2 (2.9) |
| T wave inversion | 24 (34.8) |
| QTc prolongation | 10 (14.5) |
Clinical characteristics | Positive family history | 26 (38.7) |
Documented arrhythmia | 27 (39.1) |
| Supraventricular arrhythmia | 13 (18.8) |
| AVNRT | 3 (4.3) |
| AVRT | 0 |
| Atrial fibrillation | 5 (7.3) |
| Ventricular arrhythmia | 24 (34.8) |
| VES | 20 (29.0) |
| Ventricular tachycardia | 6 (8.7) |
| Bradycardia | 8 (11.6) |
| Sudden Cardiac Death | 1 (1.5) |
Thromboembolic events | 2 (2.9) |
| Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).